Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. GOOGL
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts
(NASDAQ: VRCA) Delayed: 5.64 +0.01 (0.18%)
Previous Close $5.63    52 Week High $ 
Open $5.63    52 Week Low $ 
Day High $6.19    P/E N/A 
Day Low $5.63    EPS $ 
Volume 105,090